DynaGen, LTS Lohmann Therapie Systeme GmbH, Nastech deal

DYGN and LTS signed a memorandum of understanding for evaluation and possible development of DYGN's NicErase transdermal and buccal formulations for smoking cessation therapy. DYGN will license the NicErase technology, expertise and patents to LTS, which will develop and manufacture the product and identify distribution partners. LTS is a member of the Lohmann Group, Lohmann GmbH & Co. KG (Andernach, Germany).

DYGN also licensed its NicErase nasal spray formulation to NSTK, which anticipates filing an IND with FDA this summer. NSTK also will be responsible for identifying marketing partners. ...